A unified approach for design and analysis of transfer studies for analytical methods

被引:21
作者
Kringle, R
Khan-Malek, R
Snikeris, F
机构
[1] Sanofi Synthelabo Res, Biostat, Malvern, PA 19355 USA
[2] Sanofi Synthelabo Res, Analyt Sci, Malvern, PA 19355 USA
[3] Sanofi Synthelabo Rech, Biostat, Toulouse, France
[4] Sanofi Synthelabo Rech, Analyt Sci, Toulouse, France
来源
DRUG INFORMATION JOURNAL | 2001年 / 35卷 / 04期
关键词
technology transfer; equivalence test; sample size determination; specifications;
D O I
10.1177/009286150103500424
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Various approaches are compared for the design and analysis of studies to assess the transfer of an analytical method from a research and development site to one or more other sites: comparison of observed bias and precision to acceptance limits, statistical quality control-type analysis, statistical difference tests, and statistical equivalence tests. These approaches are evaluated in terms of the extent to which the risks of incorrect decisions (consumer risk of failing to detect that a site is unacceptable, and producer risk of rejecting an acceptable site) are known and/or controlled. Comparison of observed accuracy and precision to acceptance limits is a flawed approach because both the consumer and producer risks are unknown and uncontrolled. For technology transfer where the objective is to demonstrate sufficient acceptability or similarity, the statistical quality control and difference tests are well known to suffer from illogical characteristics (decreasing true acceptance probabilities as the sample size increases). The equivalence test is the preferred approach because it alone controls the more important consumer risk and performs in a scientifically logical manner Acceptance limits for accuracy and precision in the equivalence test should be based on need for intended use (ie, ensuring that good batches will pass, and bad batches will fail, during future release testing and stability testing), and a rigorous method for selection of well-conceived limits is presented. Methods for sample size determination are also included. The proposed approach is illustrated with two examples.
引用
收藏
页码:1271 / 1288
页数:18
相关论文
共 12 条
[1]  
Burdick R., 1992, Confidence intervals on variance components, V1st
[2]  
Chow S-C., 1992, DESIGN ANAL BIOAVAIL
[3]  
*COMM SFSTP, 2000, STP PHARM PRATIQUES, V10, P61
[4]  
*EUR COMM CLIN LAB, 1986, GUID EV AN CLN CHEM, V3
[5]   REAPPRAISAL OF HYPOTHESIS-TESTING FOR METHOD VALIDATION - DETECTION OF SYSTEMATIC-ERROR BY COMPARING THE MEANS OF 2 METHODS OR OF 2 LABORATORIES [J].
HARTMANN, C ;
SMEYERSVERBEKE, J ;
PENNINCKX, W ;
VANDERHEYDEN, Y ;
VANKEERBERGHEN, P ;
MASSART, DL .
ANALYTICAL CHEMISTRY, 1995, 67 (24) :4491-4499
[6]  
*INT C HARM, 1997, FED REG, V62
[7]  
*INT C HARM, 1995, FED REG, V60
[8]  
*NAT COMM CLIN LAB, 1997, EP5A NCCLS
[9]  
*NAT COMM CLIN LAB, 1998, EP15P NCCLS
[10]  
SIXSMITH D, 2000, PHARM TECHNOL EUR, P26